Leukemia Research
Volume 34, Issue 10 , Pages 1287-1295 , October 2010

Differential cytogenomics and miRNA signature of the Acute Myeloid Leukaemia Kasumi-1 cell line CD34+38− compartment

  • Laura Pedranzini

      Affiliations

    • Genetica Medica, Dipartimento di Medicina, Chirurgia e Odontoiatria, Università di Milano, Via A. di Rudinì 8, 20142 Milan, Italy
    • ,
  • Federica Mottadelli

      Affiliations

    • Genetica Medica, Dipartimento di Medicina, Chirurgia e Odontoiatria, Università di Milano, Via A. di Rudinì 8, 20142 Milan, Italy
    • ,
  • Simona Ronzoni

      Affiliations

    • Dipartimento di Oncologia Sperimentale, Istituto Europeo di Oncologia, Milan, Italy
    • ,
  • Franca Rossella

      Affiliations

    • Genetica Medica, Dipartimento di Medicina, Chirurgia e Odontoiatria, Università di Milano, Via A. di Rudinì 8, 20142 Milan, Italy
    • ,
  • Manuela Ferracin

      Affiliations

    • Dipartimento di Medicina sperimentale e diagnostica, sez. Microbiologia presso “Il Cubo”, Università di Ferrara, Ferrara, Italy
    • ,
  • Ivana Magnani

      Affiliations

    • Genetica Medica, Dipartimento di Medicina, Chirurgia e Odontoiatria, Università di Milano, Via A. di Rudinì 8, 20142 Milan, Italy
    • ,
  • Gaia Roversi

      Affiliations

    • Genetica Medica, Dipartimento di Medicina, Chirurgia e Odontoiatria, Università di Milano, Via A. di Rudinì 8, 20142 Milan, Italy
    • Unità di Genetica Medica, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy
    • ,
  • Patrizia Colapietro

      Affiliations

    • Genetica Medica, Dipartimento di Medicina, Chirurgia e Odontoiatria, Università di Milano, Via A. di Rudinì 8, 20142 Milan, Italy
    • ,
  • Massimo Negrini

      Affiliations

    • Dipartimento di Medicina sperimentale e diagnostica, sez. Microbiologia presso “Il Cubo”, Università di Ferrara, Ferrara, Italy
    • ,
  • Pier Giuseppe Pelicci

      Affiliations

    • Dipartimento di Oncologia Sperimentale, Istituto Europeo di Oncologia, Milan, Italy
    • ,
  • Lidia Larizza

      Affiliations

    • Genetica Medica, Dipartimento di Medicina, Chirurgia e Odontoiatria, Università di Milano, Via A. di Rudinì 8, 20142 Milan, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 02 5032 3206; fax: +39 02 5032 3206.

Received 19 October 2009 ,Revised 13 February 2010 ,Accepted 13 February 2010.

References 

  1. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730–737
  2. Buzzeo MP, Scott EW, Cogle CR. The hunt for cancer-initiating cells: a history stemming from leukemia. Leukemia. 2007;21:1619–1627
  3. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645–648
  4. Zucchi I, Sanzone S, Astigiano S, et al. The properties of a mammary gland cancer stem cell. Proc Natl Acad Sci USA. 2007;104:10476–10481
  5. Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA. 2004;101:781–786
  6. Peterson LF, Zhang DE. The 8;21 translocation in leukemogenesis. Oncogene. 2004;23:4255–4262
  7. Gelmetti V, Zhang J, Fanelli M, et al. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol. 1998;18:7185–7191
  8. Beghini A, Magnani I, Ripamonti CB, et al. Amplification of a novel c-Kit activating mutation Asn(822)-Lys in the Kasumi-1 cell line: a t(8;21)-Kit mutant model for acute myeloid leukemia. Hematol J. 2002;3:157–163
  9. Kelly LM, Gilliland DG. Genetics of myeloid leukemias. Annu Rev Genom Hum Genet. 2002;3:179–198
  10. Asou H, Tashiro S, Hamamoto K, et al. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood. 1991;77:2031–2036
  11. Rossi MR, Laduca J, Cowell JK, et al. Genomic analysis of CD8+ NK/T cell line, ‘SRIK-NKL’, with array-based CGH (aCGH), SKY/FISH and molecular mapping. Leuk Res. 2008;32:455–463
  12. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402–408
  13. Horsley SW, Mackay A, Iravani M, et al. Array CGH of fusion gene-positive leukemia-derived cell lines reveals cryptic regions of genomic gain and loss. Genes Chromosomes Cancer. 2006;45:554–564
  14. Rucker FG, Sander S, Dohner K, et al. Molecular profiling reveals myeloid leukemia cell lines to be faithful model systems characterized by distinct genomic aberrations. Leukemia. 2006;20:994–1001
  15. Larizza L, Magnani I, Beghini A. The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia. Leuk Lymphoma. 2005;46:247–255
  16. Mangino M, Brouilette S, Braund P, et al. A regulatory SNP of the BICD1 gene contributes to telomere length variation in humans. Hum Mol Genet. 2008;17:2518–2523
  17. Chan WI, Huntly BJ. Leukemia stem cells in acute myeloid leukemia. Semin Oncol. 2008;35:326–335
  18. Nishii K, Usui E, Katayama N, et al. Characteristics of t(8;21) acute myeloid leukemia (AML) with additional chromosomal abnormality: concomitant trisomy 4 may constitute a distinctive subtype of t(8;21) AML. Leukemia. 2003;17:731–737
  19. Beghini A, Larizza L, Cairoli R, et al. c-kit activating mutations and mast cell proliferation in human leukemia. Blood. 1998;92:701–702
  20. Beghini A, Ripamonti CB, Cairoli R, et al. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Haematologica. 2004;89:920–925
  21. Beghini A, Ripamonti CB, Castorina P, et al. Trisomy 4 leading to duplication of a mutated KIT allele in acute myeloid leukemia with mast cell involvement. Cancer Genet Cytogenet. 2000;119:26–31
  22. Beghini A, Tibiletti MG, Roversi G, et al. Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa. Cancer. 2001;92:657–662
  23. Dias S, Hattori K, Zhu Z, et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest. 2000;106:511–521
  24. Gerber HP, Ferrara N. The role of VEGF in normal and neoplastic hematopoiesis. J Mol Med. 2003;81:20–31
  25. Imai N, Miwa H, Shikami M, et al. Growth inhibition of AML cells with specific chromosome abnormalities by monoclonal antibodies to receptors for vascular endothelial growth factor. Leuk Res. 2009;33:1650–1657
  26. Imai N, Shikami M, Miwa H, et al. t(8;21) acute myeloid leukaemia cells are dependent on vascular endothelial growth factor (VEGF)/VEGF receptor type2 pathway and phosphorylation of Akt. Br J Haematol. 2006;135:673–682
  27. Rothlisberger B, Heizmann M, Bargetzi MJ, et al. TRIB1 overexpression in acute myeloid leukemia. Cancer Genet Cytogenet. 2007;176:58–60
  28. Czepulkowski B, Powell AR, Pagliuca A, et al. Trisomy 10 and acute myeloid leukemia. Cancer Genet Cytogenet. 2002;134:81–83
  29. Uckan D, Hicsonmez G, Yetgin S, et al. CD34/CD117 co-expression in childhood acute leukemia. Leuk Res. 2000;24:201–206
  30. Rytting ME. Pediatric myelodysplastic syndromes. Curr Hematol Rep. 2004;3:173–177
  31. Tavil B, Cetin M, Tuncer M. CD34/CD117 positivity in assessment of prognosis in children with myelodysplastic syndrome. Leuk Res. 2006;30:222–224
  32. Bolufer P, Barragan E, Collado M, et al. Influence of genetic polymorphisms on the risk of developing leukemia and on disease progression. Leuk Res. 2006;30:1471–1491
  33. Lee HS, Lee JH, Hur EH, et al. Clinical significance of GSTM1 and GSTT1 polymorphisms in younger patients with acute myeloid leukemia of intermediate-risk cytogenetics. Leuk Res. 2009;33:426–433
  34. Blair A, Hogge DE, Sutherland HJ. Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(−)/HLA-DR. Blood. 1998;92:4325–4335
  35. Shlien A, Malkin D. Copy number variations and cancer susceptibility. Curr Opin Oncol. 2010;22:55–63
  36. Guled M, Lahti L, Lindholm PM, et al. CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma-A miRNA microarray analysis. Genes Chromosomes Cancer. 2009;48:615–623
  37. Guttilla IK, White BA. Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem. 2009;284:23204–23216
  38. Schaefer A, Jung M, Mollenkopf HJ, et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 2010;126(5):1166–1176
  39. Segura MF, Hanniford D, Menendez S, et al. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci USA. 2009;106:1814–1819
  40. Dixon-McIver A, East P, Mein CA, et al. Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia. PLoS One. 2008;3:e2141
  41. Jankovic D, Gorello P, Liu T, et al. Leukemogenic mechanisms and targets of a NUP98/HHEX fusion in acute myeloid leukemia. Blood. 2008;111:5672–5682
  42. Carron C, Pascal A, Djiane A, et al. Frizzled receptor dimerization is sufficient to activate the Wnt/beta-catenin pathway. J Cell Sci. 2003;116:2541–2550
  43. Brady M, Vlatkovic N, Boyd MT. Regulation of p53 and MDM2 activity by MTBP. Mol Cell Biol. 2005;25:545–553
  44. Rau R, Brown P. Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity. Hematol Oncol. 2009;27(4):171–181
  45. Horsley V. Epigenetics, Wnt signaling, and stem cells: the Pygo2 connection. J Cell Biol. 2009;185:761–763
  46. Van Loo PF, Bouwman P, Ling KW, et al. Impaired hematopoiesis in mice lacking the transcription factor Sp3. Blood. 2003;102:858–866

PII: S0145-2126(10)00093-7

doi: 10.1016/j.leukres.2010.02.012

Leukemia Research
Volume 34, Issue 10 , Pages 1287-1295 , October 2010

Article Tools

* Image Usage & Resolution